Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a subsidiary of China-based Luye Pharma Group (HKG: 2186), has received approval from the National Medical Products Administration (NMPA) to commence a Phase I clinical trial for its proprietary antibody-drug conjugate (ADC), BA1302. The trial, which is multi-center, open-label, and involves multiple dosages with escalation and expansion, aims to evaluate the safety, tolerability, pharmacokinetic characteristics, immunogenicity, and preliminary efficacy of BA1302 in patients with advanced solid tumors. This marks a significant milestone, as BA1302 is the first ADC in China to target CD228, a glycoprotein with high specificity in various tumor expressions and known to influence tumor migration and proliferation.
The ADC, BA1302, is an innovative drug designed to harness the targeting capabilities of a fully human antibody derived from the BA huMab transgenic mouse platform, coupled with a linker payload (BNLD11) that was internally developed by Boan. This combination is expected to provide BA1302 with superior binding specificity and stability both in vitro and in vivo. Preliminary data from preclinical studies indicate that BA1302 exhibits promising internalization activity and bystander effects, suggesting its potential as a broad-spectrum anti-tumor therapy.- Flcube.com
